

Steve Sisolak
Governor
Richard Whitley, MS
Director



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
Division of Health Care Financing and Policy
Helping people. It's who we are and what we do.



Suzanne Bierman, JD, MPH
Administrator

Drug Use Review Board

Draft Meeting Minutes

Date of Meeting: Thursday, July 22, 2021

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFS), Drug Use Review Board

Agenda Item	Record	Notes																											
<p>1. Call to Order and Roll Call</p>	<p>Chairwoman Wheeler called the meeting to order at 1:13 p.m. on July 22, 2021.</p> <p>Chairwoman Wheeler took the roll.</p> <table border="0" data-bbox="772 1052 1537 1414"> <thead> <tr> <th></th> <th>Present</th> <th>Absent</th> </tr> </thead> <tbody> <tr> <td>Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Mark Canty, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crystal Castaneda, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Jessica Cate, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Mohammad Khan, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Brian Le, DO</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Present	Absent	Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Crystal Castaneda, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Mohammad Khan, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Brian Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p>The DHCFS Staff Present were as follows: Woodrum, Homa, Senior Deputy Attorney General Gudino, Antonio, Social Services Program Specialist III Flowers, Ellen, Program Officer I Olsen, David, Chief, Pharmacy Services Capurro, Antonina, Deputy Administrator</p>
	Present	Absent																											
Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Crystal Castaneda, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Mohammad Khan, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
Brian Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											

Agenda Item	Record	Notes
	<p>Michael Owens, MD <input checked="" type="checkbox"/> <input type="checkbox"/></p> <p>Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/></p> <p>A quorum was present.</p>	<p>Managed Care Organization representatives present were as follows: Bitton, Ryan, Pharm.D., Health Plan of Nevada Lim, Luke, Pharm.D., Anthem Blue Cross Beranek, Tom, RPh, SilverSummit Health Plan</p> <p>Gainwell Technologies Staff Present were as follows: Leid, Jovanna, Pharm.D.</p> <p>OptumRx Staff Present were as follows: LeCheminant, Jill, Pharm.D. Piccirilli, Annette Hansen, Sean Medina, Daniel Kiriakopoulos, Amanda, Pharm.D. Lee, Cara, Pharm.D. Whittington, Kevin, RPh</p> <p>The public attendee list is included as attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured.</p>

Agenda Item	Record	Notes																																
<p>2. General Public Comment</p>	<p>It was announced the meeting is being recorded.</p> <p>Senior Deputy Attorney General Woodrum discussed changes to the Open Meeting Law.</p> <p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No written comment was received.</p> <p>No public comment was offered.</p>																																	
<p>3. Administrative</p>																																		
<p>a. For Possible Action: Review and Approve Meeting Minutes from April 22, 2021</p>	<p>No corrections were offered.</p> <p>Board Member Canty moved to approve the minutes as presented, and Board Member Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="766 1023 1533 1347"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Mark Canty, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Brian Le, DO</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Michael Owens, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Brian Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Brian Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
<p>b. Status Update by DHCFP</p>	<p>Chief Olsen announced Antonina Capurro as the DHCFP Deputy Administrator. Chief Olsen discussed Senate Bill 190 and Senate</p>																																	

Agenda Item	Record	Notes
	<p>Bill 325, highlighting the allowance of pharmacists to prescribe and dispense medications for self-administered birth control and HIV prevention. Passage of Senate Bill 380 allowed for increased drug price transparency. Chief Olsen reported the transition process began to the new pharmacy benefit manager. Chief Olsen expressed appreciation to Dr. Carl Jeffry for his service to the State of Nevada.</p>	
<p>4. Clinical Presentations</p>		
<p>a. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Antimigraine Medications-Miscellaneous.</p>		
<p>i. <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened</p> <p>No written comment was received</p> <p>No public comment was offered.</p>	
<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. LeCheminant reviewed the proposed criteria presented in the binder and discussed the utilization of the medications in the class.</p> <p>Dr. Lim agreed with the proposed criteria and highlighted low utilization.</p> <p>Dr. Bitton was unable to present due to technical issues. Dr. LeCheminant noted Health Plan of Nevada agreed with the proposed criteria and highlighted low utilization.</p> <p>Mr. Beranek agreed with the proposed criteria and highlighted low utilization.</p>	

Agenda Item	Record	Notes																																
iii. Discussion by Board and review of utilization data.	Chairwoman Wheeler asked for comments from the Board Members. No comments were made.																																	
iv. Proposed adoption of updated prior authorization criteria.	Board Member Le moved to approve the proposed criteria as presented, and Board Member Adeolokun seconded the motion. A vote was held: <table border="0" data-bbox="766 560 1543 876" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th></th> <th style="text-align: center;">Yes</th> <th style="text-align: center;">No</th> <th style="text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>Jennifer Wheeler, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Netochi Adeolokun, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Mark Canty, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Dave England, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Brian Le, DO</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Michael Owens, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Jim Tran, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Brian Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Brian Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
b. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Duchene Muscular Dystrophy Agents.																																		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. Comment was made from Tracy Copeland of Sarepta Therapeutics that she is available to answer questions regarding Amondys 45 when it is reviewed. Senior Deputy Attorney General Woodrum encouraged comments and asked when Amondys 45 will be reviewed.																																	

Agenda Item	Record	Notes
	<p>Dr. LeCheminant stated Amondys 45 will be reviewed in the January 2022 DUR meeting.</p> <p>Tracy Copeland noted she is available to answer questions.</p> <p>Comment was made from Anna Parievsky of MS Pharma, providing information on Viltepso. Dr. Parievsky reviewed package insert information. Trials demonstrating safety and efficacy were presented. Dr. Parievsky requested Viltepso be added to the PDL.</p>	
<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. LeCheminant presented information regarding Viltepso including the indication, administration, and clinical trials demonstrating efficacy. Dr. LeCheminant reviewed the proposed criteria presented in the binder.</p> <p>Chairwoman Wheeler announced Board member Castaneda joined the meeting and is available for voting.</p> <p>Dr. LeCheminant reviewed the utilization of this class and reported no utilization for Viltepso.</p> <p>Dr. Lim proposed a policy update to require concurrent use with a corticosteroid and reported no Viltepso utilization.</p> <p>Dr. Bitton proposed a policy update prohibiting concurrent use with other exon-skipping therapies and reported no Viltepso utilization.</p> <p>Mr. Beranek proposed a policy update to require an inadequate response to an oral corticosteroid and concurrent use with an oral corticosteroid. Mr. Beranek reported no Viltepso utilization.</p>	
<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairwoman Wheeler asked for comments from the Board Members.</p>	

Agenda Item	Record	Notes																
	<p>Board Member Adeolokun requested clarification if the ambulatory and age requirements were removed from the criteria for Vyondys 53 at a previous DUR meeting.</p> <p>Dr. LeCheminant confirmed the removal of those requirements from the proposed Vyondys 53 criteria at the January 2021 DUR meeting.</p> <p>Chairwoman Wheeler stated the package insert was reviewed and did not include an age requirement.</p> <p>Board Member Castaneda discussed the benefit of this class of medications in patients under the age of four and regardless of ambulatory status.</p>																	
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Chairwoman Wheeler suggested removing the age requirement from the proposed criteria and removing the documentation requirement that the patient is ambulatory via the six-minute walk test from the initial authorization and reauthorization criteria.</p> <p>Board Member Adeolokun agreed and moved to accept the modified criteria.</p> <p>Board Member Canty seconded the motion.</p> <p>A vote was held:</p> <table data-bbox="772 1230 1522 1393"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Mark Canty, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.															
Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															
Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															
Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>															

Agenda Item	Record	Notes
	Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Brian Le, DO <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Michael Owens, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	
5. DUR Board Requested Reports		
a. For Possible Action: Opioid utilization – top prescriber and members.		
i. Discussion by the Board and review of utilization data.	<p>Chairwoman Wheeler asked for feedback from the Board to make the reports more efficient by possibly removing or restructuring the information. Reports could be moved to Appendices' to limit the discussion of the report to significant updates.</p> <p>Dr. LeCheminant presented the opioid utilization identifying total morphine equivalent dose (MED). Dr. LeCheminant highlighted the top ten members by morphine equivalent dose report and the top ten prescribers.</p> <p>The Board Members discussed the report highlighting useful information. Board Member Le expressed concern for opioid use seen with the top ten members and questioned what action can be taken. Board Member Le questioned if members are being monitored. Board Member England stated in the past, letters have been sent to the prescribers who were prescribing high amounts of opioids.</p> <p>Chief Olsen informed the Board, the internet connection for the on-site location was down for the past two minutes. Dr. Wheeler summarized what was discussed during that timeframe.</p>	

Agenda Item	Record	Notes
	<p>Chief Olsen stated Nevada Medicaid has a surveillance team and referrals to Pharmacy Services are passed on to the surveillance team.</p> <p>Chairwoman Wheeler recommends the report include the top ten members instead of the top 25 members.</p> <p>Board Member Castaneda agreed with the concern of the high utilization and commented on notification to the Nevada Board of Medicine as a possible action item.</p> <p>Board Member Canty stated advice from Council is needed for clarification on the authority of the committee. Board Member Canty is interested in reviewing opioid and diazepam claims.</p> <p>Senior Deputy Attorney General Woodrum stated that further information and options for a course of action can be requested from Nevada Medicaid and presented at the next meeting.</p> <p>The Board and Council discussed options for the motion.</p> <p>Chairwoman Wheeler requested guidelines on mechanisms of how to report action items identified in the opioid trend reports, specifically to act.</p> <p>Board Member England moved to accept the request.</p> <p>Clarification was made that the requested information would be assigned to HHS.</p> <p>Board Member England moved to update the motion to include the request for guidelines that would be assigned to the</p>	

Agenda Item	Record	Notes																																										
	<p>Department of Health and Human Services. Board Member Canty seconded.</p> <p>A vote was held:</p> <table data-bbox="772 414 1522 779"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Mark Canty, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Brian Le, DO</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Michael Owens, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>Chairwoman Wheeler suggested prior authorization information be provided at a future meeting and clarification on how the high amount of opioid use is approved. Chairwoman Wheeler asked when the criteria were last reviewed by the board.</p> <p>Dr. LeCheminant states the prior authorization information can be provided as well as member diagnosis. Dr. LeCheminant will investigate the last review of the criteria and what changes occurred.</p> <p>Chairwoman Wheeler motioned to review the criteria for utilization of opioids on a future agenda. Board Member Canty seconded.</p> <p>A vote was held:</p> <table data-bbox="1302 1388 1522 1421"> <thead> <tr> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td></td> </tr> </tbody> </table>		Yes	No	Abst.	Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Brian Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Yes	No	Abst.				
	Yes	No	Abst.																																									
Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																									
Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																									
Mark Canty, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																									
Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																									
Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																									
Brian Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																									
Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																									
Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																									
Yes	No	Abst.																																										

Agenda Item	Record	Notes
	<p>Jennifer Wheeler, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Netochi Adeolokun, Pharm.D., Vice Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Mark Canty, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Brian Le, DO <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Michael Owens, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Dr. Lim presented the opioid utilization identifying a steady MED level over time. Dr. Lim discussed the top providers and top utilizers and highlighted the low movement of the top ten prescribers.</p> <p>Dr. Bitton presented the opioid utilization trends. Dr. Bitton discussed the top prescribers noting a change in two of the top ten prescribers.</p> <p>Antonio Gudino reminded the Board members to leave their cameras on to remain visible to members of the public.</p> <p>Mr. Beranek presented the opioid utilization and the top opioid prescribers highlighting a change of one of the top ten prescribers. Mr. Beranek discussed the top members noting the diagnosis of cancer for four members, sickle cell anemia for one member, chronic pain for three members, an injured wrist for one member, and a degenerated disc issue for one member.</p>	
<p>ii. Requests for further evaluation of proposed clinical criteria to be presented at a later date.</p>	<p>The board made no requests.</p>	
<p>6. Standard DUR Reports</p>		

Agenda Item	Record	Notes
a. Review of Prescribing/ Program Trends.		
i. Top 10 Therapeutic Classes for Q3 2020 and Q4 2020 (by Payment and by Claims).	<p>Dr. LeCheminant presented the top classes with similar results over the quarter, with hemostatics on the top by spend amount and anticonvulsants in the top by claim count.</p> <p>Dr. Lim presented the top classes and identified hepatitis C agents that replaced tyrosine kinase inhibitors in 1Q2021.</p> <p>Dr. Bitton presented the top classes and identified the consistent amounts in the two quarters.</p> <p>Mr. Beranek presented the top drug classes and identified the consistency over the two quarters.</p>	
b. Concurrent Drug Utilization Review (ProDUR).		
i. Review of Q4 2020. ii. Review of Top Encounters by Problem Type.	<p>Dr. LeCheminant highlighted the prospective DUR reports and the interventions.</p> <p>Dr. Lim discussed the prospective DUR and the interventions.</p> <p>Dr. Bitton pointed out the prospective DUR report and the interventions.</p> <p>Mr. Beranek called out some differences in the prospective DUR compared to other programs but nothing unexpected.</p>	
c. Retrospective Drug Utilization Review (RetroDUR).		
i. Status of previous quarter. ii. Status of current quarter. iii. Review and discussion of responses.	<p>Dr. LeCheminant discussed the retrospective DUR initiatives during the last quarter with long-term PPI use and montelukast utilizers less than 21 yrs. without an Asthma diagnosis.</p>	

Agenda Item	Record	Notes
	<p>Dr. Lim highlighted the retrospective DUR programs including asthma and behavioral health programs and their respective outcomes. Controlled substance utilization management was discussed.</p> <p>Dr. Bitton was unable to present RetroDUR due to technical issues. Dr. LeCheminant informed the Board the RetroDUR report from the Health Plan of Nevada is available in the binder.</p> <p>Mr. Beranek discussed the retrospective DUR program highlighting the medication adherence program.</p>	
7. Closing Discussion		
a. Public Comment.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was offered.</p>	
b. For Possible Action: Date and location of the next meeting.	Chairwoman Wheeler stated the next meeting is scheduled for October 14, 2021, and the location is yet to be determined.	
c. Adjournment.	The meeting adjourned at 2:56 p.m.	

Steve Sisolak
Governor
Richard Whitley, MS
Director



DEPARTMENT OF
HEALTH AND HUMAN SERVICES
Division of Health Care Financing and Policy
Helping people. It's who we are and what we do.



Suzanne Bierman, JD, MPH
Administrator

Attachment A – Member of the Public in Attendance

Balen, Valerie
Booth, Robert
Cochrane, Tim M
Colabianchi, Jerry
Cooper, Emily
Copeland, Tracy
Daly, Austin
Donahue, Cheryl
Ferroli, Joseph
Germain, Joe Jr.
Hertzberg, Susan
Hill, Laura L
Large, David
Mackenzie, Kristin

Maynard, Kelly
Morgan, Suzanne
Nelson, Ann
Parievsky, Anna
Robinson, Lovell R
Stoots, Mary
Zarob, Michael

Attendees with no last name available:
Georgette
Dr. G (Guest)